Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 8, 2003. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 19, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share buyback transaction:
- Shares Purchased: 785,000 ordinary shares
- Purchase Date: September 5, 2003
- Price per Share: 1266.68p
- Purpose: Cancellation
Material Changes
The filing does not report material changes in operating results or financial position compared to prior periods. The primary change reported is the reduction of the company's share capital through the cancellation of 785,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items beyond the execution of the authorized share buyback.
Investor Verification Checklist
- Verify the total number of shares repurchased and cancelled against the company's latest capital structure.
- Confirm the total cost of the repurchase (785,000 shares at 1266.68p) and its impact on cash reserves.
- Check subsequent filings for the remaining authority available for share buybacks under the May 19, 2003 shareholder mandate.